A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Phase: Phase III clinical trials
Principal Investigator: Dott. Lo Russo Giuseppe
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: V940
Pathologies: Lung cancer
Eligible participants will receive neoadjuvant pembrolizumab with chemotherapy after which they will undergo potentially curative surgery.
Patients who are found to be eligible for randomization following surgery will be divided into two arms:
Arm A: Pembrolizumab will be administered in combination with V940
Arm B: Pebrolizumab will be administered in combination with placevo (control arm)
The main purpose of the study is to evaluate the safety and efficacy of V940 in combination with Pembrolizumab
Last update: 14/07/2026